FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3029453604> ?p ?o ?g. }

• W3029453604 endingPage "7510" @default.
• W3029453604 startingPage "7510" @default.
• W3029453604 abstract "7510 Background: CPX-351 (Vyxeos; daunorubicin and cytarabine liposome for injection), a dual-drug liposomal encapsulation of cytarabine [C] and daunorubicin [D], is approved by the FDA and EMA for the treatment of adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes. Primary analysis of the pivotal phase 3 study (NCT01696084) that formed the basis for these approvals evaluated patients (pts) aged 60-75 y with newly diagnosed high-risk/secondary AML and found that CPX-351 significantly improved median overall survival (OS) vs conventional 7+3, with a comparable safety profile. Here, we report the prospectively planned final 5-y follow-up results from this phase 3 study. Methods: Pts were randomized 1:1 to receive ≤2 induction cycles of CPX-351 (100 units/m 2 [C 100 mg/m 2 + D 44 mg/m 2 ] as a 90-min infusion on Days 1, 3, 5 [2nd induction: Days 1, 3]) or 7+3 (C 100 mg/m 2 /d continuously for 7 d + D 60 mg/m 2 on Days 1-3 [2nd induction: 5+2]). Pts achieving complete remission (CR) or CR with incomplete platelet or neutrophil recovery could receive up to 2 consolidation cycles. Pts could receive a hematopoietic cell transplant (HCT) at the physician’s discretion. Pts were followed until death or up to 5 y following randomization. Results: In total, 309 pts were randomized to CPX-351 (n = 153) or 7+3 (n = 156). The survival rate at 5 y was higher for CPX-351 vs 7+3 (18% vs 8%; Table). Among pts who died, the most common primary cause of death was progressive leukemia in both arms (CPX-351: 56%; 7+3: 53%). After a median follow-up of 60.65 mo, improved median OS with CPX-351 vs 7+3 was maintained: 9.33 vs 5.95 mo; Kaplan-Meier (KM) OS curves plateaued at ~30 mo. HCT was received by 53 (35%) vs 39 (25%) pts after CPX-351 vs 7+3; among these pts, the survival rate at 5 y was higher for CPX-351 vs 7+3 (52% vs 23%), and median OS landmarked from the HCT date was not reached for CPX-351 vs 10.25 mo for 7+3 (Table). Conclusions: After 5 y of follow-up, improved OS was maintained in this phase 3 study, supporting that CPX-351 has the ability to produce or contribute to long-term remission and survival in older pts with newly diagnosed high-risk/secondary AML. Clinical trial information: NCT01696084 . [Table: see text]" @default.
• W3029453604 created "2020-06-05" @default.
• W3029453604 creator A5003966906 @default.
• W3029453604 creator A5006999192 @default.
• W3029453604 creator A5007647176 @default.
• W3029453604 creator A5015101485 @default.
• W3029453604 creator A5015493242 @default.
• W3029453604 creator A5018394344 @default.
• W3029453604 creator A5026347795 @default.
• W3029453604 creator A5032665185 @default.
• W3029453604 creator A5035236340 @default.
• W3029453604 creator A5037299848 @default.
• W3029453604 creator A5039085433 @default.
• W3029453604 creator A5041443589 @default.
• W3029453604 creator A5055301938 @default.
• W3029453604 creator A5069208658 @default.
• W3029453604 creator A5078887304 @default.
• W3029453604 creator A5083412651 @default.
• W3029453604 creator A5085532403 @default.
• W3029453604 date "2020-05-20" @default.
• W3029453604 modified "2023-10-15" @default.
• W3029453604 title "Five-year final results of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed high-risk/secondary AML." @default.
• W3029453604 doi "https://doi.org/10.1200/jco.2020.38.15_suppl.7510" @default.
• W3029453604 hasPublicationYear "2020" @default.
• W3029453604 type Work @default.
• W3029453604 sameAs 3029453604 @default.
• W3029453604 citedByCount "15" @default.
• W3029453604 countsByYear W30294536042020 @default.
• W3029453604 countsByYear W30294536042021 @default.
• W3029453604 countsByYear W30294536042022 @default.
• W3029453604 countsByYear W30294536042023 @default.
• W3029453604 crossrefType "journal-article" @default.
• W3029453604 hasAuthorship W3029453604A5003966906 @default.
• W3029453604 hasAuthorship W3029453604A5006999192 @default.
• W3029453604 hasAuthorship W3029453604A5007647176 @default.
• W3029453604 hasAuthorship W3029453604A5015101485 @default.
• W3029453604 hasAuthorship W3029453604A5015493242 @default.
• W3029453604 hasAuthorship W3029453604A5018394344 @default.
• W3029453604 hasAuthorship W3029453604A5026347795 @default.
• W3029453604 hasAuthorship W3029453604A5032665185 @default.
• W3029453604 hasAuthorship W3029453604A5035236340 @default.
• W3029453604 hasAuthorship W3029453604A5037299848 @default.
• W3029453604 hasAuthorship W3029453604A5039085433 @default.
• W3029453604 hasAuthorship W3029453604A5041443589 @default.
• W3029453604 hasAuthorship W3029453604A5055301938 @default.
• W3029453604 hasAuthorship W3029453604A5069208658 @default.
• W3029453604 hasAuthorship W3029453604A5078887304 @default.
• W3029453604 hasAuthorship W3029453604A5083412651 @default.
• W3029453604 hasAuthorship W3029453604A5085532403 @default.
• W3029453604 hasConcept C126322002 @default.
• W3029453604 hasConcept C141071460 @default.
• W3029453604 hasConcept C168563851 @default.
• W3029453604 hasConcept C204243189 @default.
• W3029453604 hasConcept C2778041864 @default.
• W3029453604 hasConcept C2778461978 @default.
• W3029453604 hasConcept C2781021840 @default.
• W3029453604 hasConcept C2781413609 @default.
• W3029453604 hasConcept C31760486 @default.
• W3029453604 hasConcept C535046627 @default.
• W3029453604 hasConcept C71924100 @default.
• W3029453604 hasConcept C90924648 @default.
• W3029453604 hasConceptScore W3029453604C126322002 @default.
• W3029453604 hasConceptScore W3029453604C141071460 @default.
• W3029453604 hasConceptScore W3029453604C168563851 @default.
• W3029453604 hasConceptScore W3029453604C204243189 @default.
• W3029453604 hasConceptScore W3029453604C2778041864 @default.
• W3029453604 hasConceptScore W3029453604C2778461978 @default.
• W3029453604 hasConceptScore W3029453604C2781021840 @default.
• W3029453604 hasConceptScore W3029453604C2781413609 @default.
• W3029453604 hasConceptScore W3029453604C31760486 @default.
• W3029453604 hasConceptScore W3029453604C535046627 @default.
• W3029453604 hasConceptScore W3029453604C71924100 @default.
• W3029453604 hasConceptScore W3029453604C90924648 @default.
• W3029453604 hasFunder F4320312570 @default.
• W3029453604 hasIssue "15_suppl" @default.
• W3029453604 hasLocation W30294536041 @default.
• W3029453604 hasOpenAccess W3029453604 @default.
• W3029453604 hasPrimaryLocation W30294536041 @default.
• W3029453604 hasRelatedWork W1020360509 @default.
• W3029453604 hasRelatedWork W2053430911 @default.
• W3029453604 hasRelatedWork W2082440968 @default.
• W3029453604 hasRelatedWork W2113871094 @default.
• W3029453604 hasRelatedWork W2408756948 @default.
• W3029453604 hasRelatedWork W2417674202 @default.
• W3029453604 hasRelatedWork W2424199172 @default.
• W3029453604 hasRelatedWork W2483620080 @default.
• W3029453604 hasRelatedWork W2555266496 @default.
• W3029453604 hasRelatedWork W4283806841 @default.
• W3029453604 hasVolume "38" @default.
• W3029453604 isParatext "false" @default.
• W3029453604 isRetracted "false" @default.
• W3029453604 magId "3029453604" @default.
• W3029453604 workType "article" @default.